Pilot feasibility study of epigenetic aging biomarkers in a 4-week tree nut and olive oil diet
In 34 adults aged 48–81 with metabolic syndrome, a 4-week daily tree nut and extra virgin olive oil diet was feasible with over 95% adherence, but no significant changes in epigenetic aging measures were seen. [1]
Automatic summary · not editorially reviewed
The key findings
The pilot feasibility study included 34 adults aged 48–81 years with metabolic syndrome who consumed 1 oz of tree nuts and two tablespoons of extra virgin olive oil daily for 4 weeks. [1]
At baseline, all participants had a faster pace of biological aging than average on DunedinPACE, and adherence to the diet exceeded 95%. [1]
No significant changes in epigenetic aging were observed over the 4-week intervention, and the authors describe the work as a pilot feasibility study. [1]
The source at a glance
- Study type / format
- Pilot feasibility study (abstract)
- Population / context
- 34 adults aged 48–81 years with metabolic syndrome
- Summary based on
- Study abstract
- Original publication
- July 29, 2026
Metabolic syndrome pilot with 34 adults
The authors describe a pilot feasibility study among 34 adults aged 48–81 years with metabolic syndrome, a condition they link to elevated risk of age-related cardiometabolic disease and advanced biological aging. Participants consumed 1 oz of tree nuts and two tablespoons of extra virgin olive oil daily for 4 weeks. The primary objectives were feasibility, adherence and participant acceptability of epigenetic aging assessments; exploratory outcomes were DunedinPACE, a measure of the pace of aging, and AgeAccelGrim, a measure of biological age relative to chronological age.
Supporting source [1]
Faster baseline aging and over 95% adherence
At baseline, all participants showed a faster pace of biological aging than average on DunedinPACE, which the authors say supports metabolic syndrome as a promising target population for geroscience interventions. Adherence to the dietary intervention exceeded 95%, and most participants said they would join a similar longer-term trial. Participants were strongly interested in learning their biological age and said evidence of slowed aging would motivate sustained dietary change. No significant changes in epigenetic aging were observed over the 4 weeks.
Supporting source [1]
Feasibility signals, not evidence of slowed aging
The authors conclude that the findings show feasibility and acceptability of including epigenetic aging biomarkers in dietary intervention research, and suggest such measures may serve both as surrogate outcomes and as tools for participant engagement. They also present metabolic syndrome as a relevant population for dietary geroscience trials and offer practical guidance for longer-term studies testing whether diet can slow biological aging. The 4-week pilot was not designed to detect or demonstrate slowed aging; the absence of significant epigenetic changes over this short period is a limit on what the results can show.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This was a 4-week pilot feasibility study with 34 participants and no control group described; epigenetic aging measures were exploratory, and the short duration limits conclusions about slowing biological aging.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Lindsay M. Reynolds, Timothy D. Howard, Carl D. Langefeld, Mara Z. Vitolins · doi.org · July 29, 2026